ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC

For patients with advanced non-small cell lung cancer (NSCLC), indefinite duration of immunotherapy treatment does not seem to offer benefits over fixed-duration therapy for two years, according to a study published online June 4 in JAMA Oncology to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago.

Lova Sun, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues conducted a retrospective, population-based cohort study involving adults diagnosed with advanced NSCLC from 2016 to 2020 who received frontline immunotherapy-based treatment. Practice patterns surrounding treatment discontinuation at two years (between 700 and 760 days; fixed duration) versus continued treatment beyond two years (greater than 760 days; indefinite duration) were compared. Of 1,091 patients who were still on immune checkpoint inhibitor (ICI) treatment at two years, 113 and 593 were in the fixed-duration and indefinite-duration groups, respectively.

Source: Advances and More licensed by HealthDay

https://advancesandmore.com/advances_article.htm?id=2660896586&client=BEE80FAF&section=undefined